NASA’s COVID-19 ventilator gains FDA approval for emergency use
The Food and Drug Administration yesterday approved for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
NASA’s VITAL (Ventilator Intervention Technology Accessible Locally) system is designed to last three to four months and is specifically tailored for patients with COVID-19 by providing respiratory support for patients experiencing respiratory failure or insufficiency.
Additionally, the device is designed to be built with components outside the current medical device supply chain and thereby will not impact existing ventilator supply chains.
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…